These press releases are intended for business journalists and analysts/investors
GSK Australia is proud to be partnering with the Australian Government to re-introduce a diphtheria, tetanus, acellular pertussis (DTPa) vaccine on the National Immunisation Program for children at 18-months of age.
New research conducted on behalf of Voltaren and GSK Consumer Healthcare shows that 97 percent of Australians suffer from body aches, with a massive two thirds (68%) experiencing it at least weekly, higher than the other 13 countries included in the survey. Findings show pain impacts our social life, love life, performance at work and ability to parent.
Read more - Australia leads the world in body pain blues Read more
GSK has launched a new immunology research collaboration model – the Immunology Catalyst sabbatical program – designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology.
Australian Professor John Hamilton from the University of Melbourne was the first academic to join the program.
GSK prioritises whooping cough vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Boostrix® to all Australian State, Territory and Federal Government vaccination programs where Boostrix is the vaccine of choice.
GSK is leading the pharmaceutical sector by being first in Australia to introduce a new framework for its medical education program and interactions with healthcare professionals to increase transparency.
Read more - GSK first in Australia with new business model for the pharmaceutical industry Read more
- Assistant Minister for Science Karen Andrews opens new vaccine facility in Boronia, Victoria
- GSK awarded $1 million Federal Government grant for advanced manufacturing project
- Three-year pilot to test commercialisation
Amgen and GSK to Work Together to Ensure a Smooth Transition for
Prolia® Patients and Their Physicians
Read more - Amgen reacquires all rights to Prolia® (denosumab) in Australia Read more
Australian researchers awarded $80,000 for breakthrough in immunity
Millions more children from the world’s poorest countries are being vaccinated against more diseases than ever before.
GSK Australia is proud to be partnering with the Australian Government to provide a quadrivalent (four-strain) influenza vaccine for the National Immunisation Program (NIP) for the 2016 season.